Xiamen UX IC (688807.SH) Chairman Proposes Share Buyback of RMB 100 Million to RMB 200 Million
UX IC (688807.SH) announced that on October 19, 2026, the company's board of directors received a letter from Mr. Ke Binglin, one of the company's actual controllers and the chairman, titled "Letter Regarding the Proposal to Repurchase Shares of Xiamen UX IC Co., Ltd." Mr. Ke Binglin proposed that the company use its own funds or self-raised funds to repurchase a portion of its issued RMB ordinary shares (A shares) through the Shanghai Stock Exchange trading system by way of centralized bidding. The total amount of funds for the share repurchase shall be no less than RMB 100 million (inclusive) and no more than RMB 200 million (inclusive). The repurchased shares will all be used for employee stock ownership plans or equity incentives at appropriate times in the future.
Xiamen UX IC (688807.SH) announced that on October 19, 2026, the company's board of directors received a letter from Mr. Ke Binglin, one of the company's actual controllers and its chairman, titled "Letter Regarding the Proposal to Xiamen UX IC Co., Ltd. to Repurchase the Company's Shares." Mr. Ke Binglin proposed that the company use its own funds or self-raised funds to repurchase part of its issued RMB ordinary shares (A shares) through the Shanghai Stock Exchange trading system by way of centralized bidding. The total amount of funds for the share repurchase shall be no less than RMB 100 million (inclusive) and no more than RMB 200 million (inclusive). The repurchased shares will all be used for an employee stock ownership plan or equity incentive at an appropriate time in the future.
Related Articles
Chengdu Olymvax Biopharmaceuticals Inc(688319.SH) received the Phase III clinical study summary report for the recombinant Staphylococcus aureus vaccine (E. coli)
US Stock Market Move | Amazon.com, Inc. (AMZN.US) rose nearly 4%; Morgan Stanley named it a top pick and raised its price target to $350.
AI agent adoption may be constrained by compute bottlenecks; Morgan Stanley remains bullish on Meta's (META.US) long-term commercialization prospects, raises target price to $820 and maintains "Overweight" rating.
Chengdu Olymvax Biopharmaceuticals Inc(688319.SH) received the Phase III clinical study summary report for the recombinant Staphylococcus aureus vaccine (E. coli)
US Stock Market Move | Amazon.com, Inc. (AMZN.US) rose nearly 4%; Morgan Stanley named it a top pick and raised its price target to $350.
AI agent adoption may be constrained by compute bottlenecks; Morgan Stanley remains bullish on Meta's (META.US) long-term commercialization prospects, raises target price to $820 and maintains "Overweight" rating.
